<DOC>
	<DOCNO>NCT00483067</DOCNO>
	<brief_summary>Primary Objectives : 1 . To determine response rate , progression-free survival ( PFS ) overall survival patient receive 2-CdA + Ara-C. 2 . To examine clonality cytokine expression helper T cell cytokine receptor expression eosinophil . 3 . To determine effect 2-CdA accumulation Ara-C triphosphate eosinophil .</brief_summary>
	<brief_title>2-Chlorodeoxyadenosine Cytarabine Patients With Idiopathic Hypereosinophilic Syndrome ( HES )</brief_title>
	<detailed_description>Before study begin , patient physical exam , blood test , urine test . Women pregnancy test . A bone marrow sample take . This do large needle . Heart test MRI scan brain do suspicion disease heart central nervous system . Patients study must catheter ( thin tube ) place vein arm collarbone . This tube leave place throughout study . 2-CdA ( Cladribine ) give catheter 24 hour day day 2 6 . Ara-C ( Cytarabine ) give catheter 2 hour day 1 , 3 , 4 , 5 , 6 . Starting day 9 , patient inject G-CSF skin day ; G-CSF help blood count return normal . Treatment give inpatient outpatient basis . The first course normally do inpatient . During study , patient blood test daily first week every day . Bone marrow sample take day 14 , 21 , 28 . Further bone marrow sample may necessary evaluate response . Heart test MRI scan brain may do . This investigational study . G-CSF , 2-CdA , Cytarabine approve FDA treatment cancer . Up 40 patient take part study . Patients treat M. D. Anderson center . A total 40 people take part study . About 1 patient every 3 month enrol M. D. Anderson .</detailed_description>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patient must diagnosis idiopathic HES , define ( 1 ) recent history allergic reaction parasitic infection ; ( 2 ) sustain ( &gt; 6 month ) hypereosinophilia ( 1,500/mm^3 ) ; ( 3 ) sign symptom organ involvement . 2 . Age le 76 year old . 3 . Patient pregnant . 4 . Zubrod performance status &lt; 3 . 5 . Life expectancy severely limited concomitant illness . 6 . Serum creatinine &lt; 2 mg/dL . 7 . Serum bilirubin &lt; 2 time upper limit normal ( 2 mg/dL ) . 8 . Alanine aminotransferase ( SGPT ) &lt; 2 time upper limit normal ( 112 IU/L ) . 9 . Participant complete informed consent process , understand investigational nature study , agree participate , sign informed consent . 1 . Evidence chronic active hepatitis cirrhosis , &gt; 1 month prior episode hepatitis . 2 . Presence active infection . 3 . HIV positive . 4 . Has eosinophilic leukemia ( define presence clonal cytogenetic abnormality ) . 5 . Recent history parasite infection . 6 . Recent history allergic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Idiopathic Hypereosinophilic Syndrome</keyword>
	<keyword>Leukemia</keyword>
	<keyword>2-Chlorodeoxyadenosine</keyword>
	<keyword>Cladribine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>2-CdA</keyword>
	<keyword>G-CSF</keyword>
	<keyword>HES</keyword>
</DOC>